Biotech Startups

Kasvu is a drug-discovery company developing small-molecule neuroplastogens — selective positive allosteric modulators of the TrkB receptor — using an AI-powered 3D model of the receptor and structure-based drug design. Its molecules aim to improve neuronal plasticity and cognitive function as treatments for neuropsychiatric conditions and neurodegenerative diseases such as Alzheimer's and Parkinson's.

1 investor

QuTEM provides electron microscopy analytics with proprietary software (Gridsee) for quality control of gene therapies, enabling manufacturers to ensure safety and consistency at regulatory and production scale. The company serves pharmaceutical and gene therapy manufacturers navigating commercialization and regulatory approval requirements.

1 investor

1 investor

Kawa Project produces a cocoa powder alternative derived from processed coffee waste using food science and manufacturing techniques. The company serves the food and beverage industry seeking sustainable ingredients.

1 investor

1 investor

Kemin develops and manufactures specialty ingredients across areas including human and animal nutrition, pet food, plant science, and health applications. The company operates globally, serving customers in more than 120 countries with over 500 specialty ingredients.

1 investor

Kentegra produces concentrated liquid insecticidal extracts derived from pyrethrum flowers for use in household, agricultural, animal health, and public health pest control applications. The company's products are naturally derived, photo-degradable active ingredients suitable for formulation into consumer and professional pest management products.

1 investor

kēpos produces a microbiome health supplement formulated to support digestive health, developed in partnership with the University of Chicago. The product targets individuals seeking science-backed digestive wellness solutions.

1 investor

Kerafast is an online marketplace that distributes laboratory reagents and research materials sourced from academic and research institutions, making individual scientists' unique reagents available to the global research community. It serves life science researchers and connects laboratories that produce specialized reagents with those seeking them.

1 investor

Clinical-stage Boston biotech developing oral pan-KRAS inhibitors for patients with KRAS-driven cancers.

1 investor

Keylika develops a platform synthesis technology for mixed ligand metal complexes to generate organometallic drugs for treating therapeutic conditions including hematology, pain, inflammation, metabolic disorders, infectious diseases, and oncology. The company combines drug development with drug delivery technologies, customizing molecular structure and formulation to optimize clinical outcomes for women, children, elderly, and patients with specific diseases.

1 investor

Keyron develops ForePass, a fully endoscopic, non-invasive and reversible gastric bypass medical device intended to reproduce the effects of metabolic surgery for patients with Class II & III obesity, type 2 diabetes, MASH/NASH, and liver fibrosis. The company targets severe "diabesity" patients who refuse surgery or do not achieve results with drugs, across the US and EU5 markets.

1 investor

KeystoneBio provides an underwriting engine that automates analysis of clinical trials, deals, and competitive data for biotech investors. The platform is designed for private and public market investors to conduct research, diligence, and portfolio management.

1 investor

Khanda is a biotech company builder that translates validated and emerging biological insights into new biotechnology companies focused on orthogonal, combination-based therapeutic approaches. It develops medicines aimed at chronic diseases, with a team of drug developers, scientists, and company builders.

1 investor

KIDEMIS produces mycelium-based protein ingredients for aquafeed, made from upcycled agricultural sidestreams, to replace wild fish and shrimp meal in the aquaculture industry. Its products aim to make aquaculture more sustainable and reduce pressure on wild fish stocks and agricultural land.

1 investor

KiinOS is a scientific intelligence platform that connects experimental results, generates insights, and supports planning and execution of scientific work. It offers flexible integrations for various research use cases and serves scientific and research organizations.

1 investor

KIJI Tx develops gene-engineered iPSC-derived MSC cell therapies for treating a broad range of inflammatory diseases, with a lead product using IL10 and CXCR4 transduction. The company works in collaboration with research institutions including CIBER, Fundación Jiménez Díaz, and CIEMAT.

1 investor

Kilele Health develops biosensing medical devices for patient monitoring and diagnostics. The company combines advanced biosensing technology with expertise in medtech development and commercialization to serve healthcare providers and patients.

1 investor

Kilobaser develops tabletop DNA and RNA synthesizers designed for laboratory professionals to produce custom oligonucleotides on demand. The company targets life science researchers and lab professionals seeking independent access to genetic material synthesis.

1 investor

Kimia Farma is an Indonesian pharmaceutical company operating across the value chain, including raw material and drug manufacturing (ethical, generic, OTC, and herbal medicines and medical devices), national pharmaceutical distribution, retail pharmacy, and health clinics and laboratories. It runs over 1,300 retail outlets, around 400 health clinics, and a distribution network reaching more than 30,000 channels in Indonesia.

1 investor

Kindling Bio develops targeted cancer gene therapy for children that uses the immune system to fight a range of tumors. The company focuses on pediatric oncology, aiming to replace toxic adult-designed therapies with treatments tailored to children's biology.

1 investor

Kingdom Superculture develops functional health ingredients derived from natural microbes, targeting consumers seeking effective nutritional and health products. The company combines microbiology expertise with data science to engineer microbe-based ingredients.

1 investor

Kinish uses plant molecular farming on 20cm dwarf rice grown in plant factories to produce milk proteins, creating dairy alternatives such as ice cream and cheese without animal sources. The company develops plant-based food products aimed at matching the taste of conventional dairy for sustainability-focused consumers.

1 investor

Kiniksa is a global biopharmaceutical company that discovers and develops novel therapies for patients with unmet medical needs, with a focus on cardiovascular diseases and related conditions. The company has an FDA-approved therapy and multiple clinical-stage assets in its pipeline.

1 investor